Prone position ventilation combined with high-flow nasal cannula oxygen therapy in patients with pulmonary infection: a retrospective study on evidence-based nursing practice - Scorecard - MDSpire
Advertisement
Prone position ventilation combined with high-flow nasal cannula oxygen therapy in patients with pulmonary infection: a retrospective study on evidence-based nursing practice
Clinical Scorecard: Evaluation of Prone Ventilation and High-Flow Nasal Cannula Oxygen Therapy in Patients with Pulmonary Infections: A Retrospective Analysis of Evidence-Based Nursing Approaches
At a Glance
Category
Detail
Condition
Pulmonary infections
Key Mechanisms
Prone position ventilation (PPV) and high-flow nasal cannula (HFNC) oxygen therapy improve oxygenation and reduce complications.
Target Population
Patients with pulmonary infections requiring respiratory support.
Care Setting
Tertiary hospitals
Key Highlights
PPV combined with HFNC showed greater improvements in PaO2/FiO2 ratio and SpO2 compared to conventional therapy.
Total complications were significantly lower in the observation group (9.0% vs. 45.0%).
ICU admission rates were reduced in the observation group (5.0% vs. 19.0%).
Length of hospital stay was shorter in the observation group (8.7 ± 2.4 days vs. 12.0 ± 2.9 days).
Nurse-assessed comfort and compliance scores were higher in the observation group.
Guideline-Based Recommendations
Diagnosis
Assess for acute respiratory failure due to pulmonary infection.
Management
Consider PPV combined with HFNC for patients with hypoxemic respiratory failure.
Monitoring & Follow-up
Monitor oxygenation indices (PaO2/FiO2 ratio, SpO2) and respiratory rate.
Risks
Be aware of potential complications and the need for ICU admission.
Patient & Prescribing Data
Critically ill patients with pulmonary infections.
HFNC can reduce the need for mechanical ventilation and improve patient comfort.
Clinical Best Practices
Implement evidence-based nursing protocols to enhance patient comfort and compliance.
Utilize combined therapies of PPV and HFNC for optimal respiratory outcomes.
Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.
